Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 4

1(16.7%)

6Total

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01940185Completed

A Post-Approval Study of the LINX® Reflux Management System

Role: lead

NCT02429830Not ApplicableCompleted

LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy

Role: lead

NCT01624506Completed

Observational Study of Anti-Reflux Surgery

Role: lead

NCT01058070Not ApplicableCompleted

An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter

Role: lead

NCT04007250Completed

FENIX™ Continence Restoration System Registry

Role: lead

NCT02505945Phase 4Completed

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

Role: lead

NCT00776997Not ApplicableCompleted

LINX Reflux Management System Clinical Study Protocol

Role: lead

NCT01625221Not ApplicableCompleted

Feasibility Study of the Magnetic Anal Sphincter (FENIX System)

Role: lead

NCT02762487Not ApplicableTerminated

RELIEF Europe Study

Role: lead

All 9 trials loaded